This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Gaining insight into the use of Adakveo following the EMA recommendation to revoke authorization.
Ticker(s): NVSWho's the expert?
- stopped seeing patients in Feb 2022
- Remains active with 2 SCD grants submitting a manuscript to Haematologica
Interview GoalTo discuss the current treatment landscape and the use of Adakveo (crizanlizumab-tmca) for the treatment of sickle cell related pain crises.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
